KMKlim McPherson

Klim McPherson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Klim McPherson has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Preferences and understanding their effects on health

    by K McPherson, A Britton

    Preference for a particular intervention may, possibly via complicated pathways, itself confer an outcome advantage which will be subsumed in unblind randomised trials as part of the measured effectiveness of the intervention. Where more attractive interventions are compared with less attractive ones, any difference could therefore be a consequence of attractiveness and not its intrinsic worth. For health promotion interventions this is clearly important, but we cannot tell how important it is for therapeutic interventions without special studies to measure or refute such effects. These are difficult to do and are complex. Until the therapeutic effects of preference itself are more clearly understood, understanding the true therapeutic effects will be compromised, at least in principle.


  • Open Access

    Public health does not need to be led by doctorsForAgainst

    by Klim McPherson, Sarah Taylor, Edward Coyle


    • 1 June 2000
      • Vol. 9  (3) , 185-91

    H2-receptor antagonists may increase the risk of cardio-oesophageal adenocarcinoma: a case-control study.

    by U L Suleiman, M Harrison, A Britton, K McPherson, T Bates

    Adenocarcinoma of the lower oesophagus and the gastric cardia has shown a dramatic worldwide increase in incidence over the last 25 years, but the cause is unknown. A large number of drugs have been introduced over this period of time, and it has been suggested that drugs that relax the lower oesophageal sphincter (DRLOS) might be causative, and on the other hand that non-steroidal anti-inflammatory drugs (NSAIDS) may be protective. H2-receptor antagonists (H2RAs) may allow achlorhydric reflux to continue without symptoms, and it is postulated that such asymptomatic reflux is uncontrolled by the usual conservative measures and may lead to increased oesophageal damage. H2RAs were first marketed in 1970 and might be the cause of the observed increase of cardio-oesophageal adenocarcinoma (COA). In a case-control study, the records of 56 subjects who died of COA in the period 1 January 1990 to 31 December 1992 were compared with those of 56 age-/sex-matched controls who died of myocardial infarction. They were 28 females and 84 males, mean age 69.8 years. The NHS records containing the lifetime prescription history of each subject were retrieved from the health authority. Each prescription was recorded, omitting drugs taken in the two years before diagnosis. Analysis was performed using conditional logistic regression. Other variables, including the use of antacids, steroids, smoking and alcohol, were also examined. Subjects dying of COA were more likely to have consumed H2RAs (relative risk (RR) 7.50, 95% CI 1.33-42.09, P < 0.02). On the other hand, they were less likely to have consumed NSAIDs (RR 0.16, 95% CI 0.03-0.93, P < 0.04) or DRLOS (RR 0.14, 95% CI 0.02-1.0, P = 0.05). This study supports a protective effect from NSAIDs against COA, but the similar effect of DRLOS is related to the increased use of cardiac drugs in the control group. H2RAs appear to have a harmful effect, which may be related to the worldwide increase in COA. However, the trend may have been apparent before cimetidine was widely available, and it is possible that the cause is multi-factorial.


  • Arguments in editorial were not "biologically implausible"

    by Klim McPherson

    EDITOR—In a news article Woodman reports that “controversy about the contraceptive pill and its effect on the risk of breast cancer was rekindled” in an editorial that I wrote in the Journal of Epidemiology and Community Health. 1 The editorial was intended in part to reduce undue complacency about the safety of the pill. Ex cathedra statements by Professor John Guillebaud in Woodman's article—that my argument “is biologically implausible”—need to be well justified, since …

  • Pain Levels After Total Hip Replacement: Their Use As Endpoints For Survival Analysis

    by A. R. Britton, D. W. Murray, C. J. Bulstrode, K. McPherson, R. A. Denham

    PAIN LEVELS AFTER TOTAL HIP REPLACEMENT


    • 1 September 1996
      • Vol. 78  (5) , 802-8

    Long-term comparison of Charnley and Stanmore design total hip replacements.

    by A R Britton, D W Murray, C J Bulstrode, K McPherson, R A Denham

    We reviewed the records of the long-term outcome of 208 Charnley and 982 Stanmore total hip replacements (THR) performed by or under the supervision of one surgeon from 1973 to 1987. The Stanmore implant had a better survival rate before revision at 14 years (86% to 79%, p = 0.004), but the difference only became apparent at ten years. The later Stanmore implants did better than the early ones (97% to 92% at ten years, p = 0.005), the improvement coinciding with the introduction of a new cementing technique using a gun. Most of the Charnley implants were done before most of the Stanmore implants so that the difference between the results may in part be explained by improved methods, but this is not the complete explanation since a difference persisted for implants carried out during the same period of time. We conclude that improved techniques have reduced failure rates substantially. This improvement was much greater than that observed between these two designs of implant. Proof of the difference would require a very large randomised controlled trial over a ten-year period.